共查询到19条相似文献,搜索用时 187 毫秒
1.
手术加顺铂腹腔灌注及联合化疗治疗晚期上皮性卵巢癌的疗效观察 总被引:2,自引:0,他引:2
目的:对晚期上皮性卵巢癌患者行手术加顺铂腹腔灌注及联合化疗,并对其疗效进行评价,以期对治疗提供帮助。方法:从我院1995年6月-1997年6月住院治疗的卵巢癌患者中筛选出晚期上皮性卵巢癌31例,均行手术治疗,术后采用PAC方案联合化疗。顺铂50-70mg/m^2腹腔灌注,阿霉素40-60mg/m^2、环磷酰胺600-800mg/m^2静脉推注,平均4-5周为一疗程,总疗程数6-12个。结果:Ⅲ期患者总有效率为77.8%;3年生存率59.1%,5年生存率为31.8%。Ⅳ期患者总有效率为66.7%;3年生存率33.3%,5年生存率为0。结论:彻底的手术加顺铂腹腔灌注并辅以静脉联合化疗为治疗晚期上皮性卵巢癌的有效途径,可相应提高患者的生活质量及生存率。 相似文献
2.
双路途径腹腔化疗加静脉化疗治疗卵巢恶性肿瘤疗效观察 总被引:1,自引:0,他引:1
目的:研究双路途径腹腔化疗加静脉化疗治疗晚期卵巢恶性肿瘤疗效。方法:52例晚期卵巢恶性肿瘤患者,腹腔加静脉化学治疗,腹腔化疗采取单针腹腔穿刺,腹腔用药:顺铂(DDP)80mg/m^2~100mg/m^2,足叶乙苷(VP16)200mg/m^2,静脉用药:环磷酰胺(CTX)600mg/m^2~800mg/m^2,每3周1周期,化疗4周期~6周期。结果:总有效率86.53%。1a、2a、3a、4a、5a生存率分别为86.53%、73.07%、65.38%、57.69%、44.23%,最长1例生存期已达10a以上,无严重毒副反应发生。结论:双路途径腹腔化疗加静脉化疗治疗晚期卵巢恶性肿瘤,有效率较高,毒副作用较轻,可望使晚期卵巢恶性肿瘤患者的化疗适应范围增加,使更多患者能提高生存质量,延长生存期。 相似文献
3.
4.
目的:评价卵巢癌术后早期腹腔热灌注化疗疗效。方法:将2002年1月-2005年12月我科收治晚期上皮性卵巢癌减瘤术后患者80例,随机单盲分成实验组40例(紫三醇联合卡铂方案静脉全身化疗联合腹腔热灌注顺铂化疗组)与对照组40例(紫三醇联合卡铂方案静脉全身化疗组)。分析两组生存率、复发情况及不良反应。结果:80例病人均完成全部6周期静脉全身化疗,实验组静脉全身化疗期间同期完成腹腔热灌注化疗6次。实验组患者术后3年生存率,5年生存率70%,55%,高于静脉全身化疗组42.5%,32.5%,不良反应可耐受。结论:术后早期腹腔热灌注化疗是晚期卵巢癌减瘤术后的有效辅助化疗,不良反应可耐受,可提高晚期卵巢癌病人的生存率和生活质量。 相似文献
5.
目的探讨胃体贲门癌全胃切除术后腹腔热灌注化疗联合全身化疗对腹腔内复发或转移的影响。方法304例胃癌术后患者随机分为两组:治疗组(160例)应用腹腔热灌注化疗,即卡铂(CBP)0.2g/m^2+丝裂霉素6mg/m^2+5-氟尿嘧啶(5-Fu)1.0g/m^2+斑螫酸钠维生素跣1.0mg/m^2+0.9%氯化钠注射液1500~2000ml(40℃~44℃)+地塞米松10mg+利多卡因20mg,热灌注化疗后加用辅助静脉化疗。对照组(144例)仅做辅助静脉化疗,两组4周为1个化疗周期,均实行4~6个周期。结果1、3、5年生存率分别为:治疗组83.8%、56.2%、39.4%,对照组80.6%、45.1%、29.9%,两组比较差异有统计学意义;5年中肝转移率、腹腔转移率、腹腔积液发生率,治疗组分别是30.0%、21.9%、30.0%,对照组分别为38.2%、36.1%、35.4%,两组比较差异有统计学意义;两组化疗的毒副作用比较差异无统计学意义。结论胃体贲门癌全胃切除术后腹腔热灌注化疗是提高胃癌术后患者生存率的有效措施。 相似文献
6.
骨肉瘤的新辅助化疗 总被引:3,自引:0,他引:3
目的:对36例采用新辅助化疗的骨肉瘤患者进行回顾性分析.方法:36例骨肉瘤患者均采用新辅助化疗。第1周期AP方案:用法ADM 60mg/m^2、DDP 120mg/m^2;第2、3周期大剂量MTX方案:MTX 200mg/kg或8g/m^2(成人),12g/m^2(儿童);第4周期IFO方案:IFO 2g/m^2,连用5天,每一周期间隔10~15天.4个周期为1疗程;术前化疗2个疗程,术后化疗3~4个疗程。结果:采用新辅助化疗的36例患者中,最终保肢率为(30/36)833%,1~3年生存率(36/36)100%,4年生存率(26/36)72.2%,5年生存率(20/36)55.6%,随访率100%。结论:新辅助化疗不仅可以提高骨肉瘤患者的生存率,尚可增加保肢手术成功率,提高患者的生存质量。 相似文献
7.
目的:评价卵巢癌术后早期腹腔热灌注化疗疗效。方法:将2002年1月-2005年12月我科收治晚期上皮性卵巢癌减瘤术后患者80例,随机单盲分成实验组40例(紫三醇联合卡铂方案静脉全身化疗联合腹腔热灌注顺铂化疗组)与对照组40例(紫三醇联合卡铂方案静脉全身化疗组)。分析两组生存率、复发情况及不良反应。结果:80例病人均完成全部6周期静脉全身化疗,实验组静脉全身化疗期间同期完成腹腔热灌注化疗6次。实验组患者术后3年生存率,5年生存率70%,55%,高于静脉全身化疗组42.5%,32.5%,不良反应可耐受。结论:术后早期腹腔热灌注化疗是晚期卵巢癌减瘤术后的有效辅助化疗,不良反应可耐受,可提高晚期卵巢癌病人的生存率和生活质量。 相似文献
8.
对晚期上皮性卵巢癌减瘤术后辅助化疗及放疗的结果进行比较分析。材料与方法对52例已行初次减瘤术的Ⅲc、Ⅳ期上皮性卵巢癌病人随机分成腹腔化疗+静脉化疗(化疗组)和放疗+静脉化疗(放疗组)2组,给予药物及放射治疗。结果化疗及放疗2组病人5年生存率分别是27.3%和36.7%,无明显差异。无严重并发症。结论对控制晚期上皮性卵巢癌减瘤术后腹腔残余癌,腹腔化疗+静脉化疗及放疗+静脉化疗同样有效,且较术后单纯静脉化疗效果好。 相似文献
9.
目的对Ⅲ~Ⅳ期上皮性卵巢癌患者行手术加单针穿刺腹腔及静脉联合化疗,并对其疗效进行评价,以期为治疗提供帮助.方法从1996年3月至1999年3月住院治疗的卵巢癌患者中筛选出晚期上皮性卵巢癌24例,均行手术治疗,术后采用PAC方案联合化疗.顺铂50~70 mg/m2,腹腔灌注;吡喃阿霉素40~60 mg/m2;环磷酰胺600~800 mg/m2,静脉注射,平均4~5周一个疗程,总共6~12疗程.结果Ⅲ期患者总有效率77.8%,Ⅳ期患者总有效率66.7%.结论彻底的手术加单针穿刺腹腔联合静脉化疗为治疗Ⅲ~Ⅳ期上皮性卵巢癌的有效途径,可提高患者的生活质量及生存期. 相似文献
10.
消化道肿瘤腹腔化疗效果及不良反应观察 总被引:1,自引:0,他引:1
目的研究晚期消化道恶性肿瘤腹腔化疗的疗效及不良反应。方法37例晚期消化道肿瘤病人,采取单针腹腔穿刺,腹腔用药:5-氟脲嘧啶(5-Fu)l000mg/m^2,顺铂(DDP)80~100mg/m^2,足叶乙甙(Vp—16)200mg/m^2,每3周为一周期,化疗4~6周期。结果总有效率32.4%,中位生存期12.6月,1年生存率为35.1%,2年生存率为12.5%,最长1例生存达39个月,无严重毒性反应发生。结论本组采用单次穿刺腹腔联合化疗,操作安全简便,有效率较高,而毒副反应较轻,可望使晚期消化道肿瘤患者的化疗适应范围增加,使更多病人能提高生存质量及生存期。 相似文献
11.
目的 探讨紫杉醇(PTX)腹腔灌注化疗联合顺铂(PDD)全身化疗治疗晚期卵巢癌患者的疗效和安全性.方法 2006年1月至2010年1月,给予33例TNMⅢ-Ⅳ期卵巢癌患者(Ⅲ期20例,Ⅳ期13例)PTX 60mg/m2 ip d1,5,10,PDD 40mg/m2 iv d1-2,每21天为1周期,共2-4个周期,每2周期评定疗效.结果 总有效率(RR,CR+PR)为78.79%,其中CR 60.61%、PR 18.18%.中位疾病进展时间(TTP)为22.3个月.2年生存率为81.82%.常见不良反应为骨髓抑制、腹痛、腹泻、胃肠道反应、脱发、口腔黏膜炎和肌肉关节痛等.结论 PTX 60mg/m2腹腔灌注d1,5,10联合PDD 40mg/m2静脉滴注d1,2方案治疗晚期卵巢癌疗效肯定,且不良反应可以耐受. 相似文献
12.
Mace L Rothenberg P Y Liu Patricia S Braly Sharon P Wilczynski Edward V Hannigan Scott Wadler Gavin Stuart Caroline Jiang Maurie Markman David S Alberts 《Journal of clinical oncology》2003,21(7):1313-1319
PURPOSE: The median survival time for women with optimally debulked adenocarcinoma of the ovary treated with intravenous (IV) chemotherapy is 41 to 52 months, and the 2-year survival rate is 65% to 70%. Recent studies evaluating intraperitoneal (IP) chemotherapy have reported a median survival time of 49 to 63 months and 2-year survival rates of 70% to 80%. This phase II trial was undertaken to evaluate the feasibility of and 2-year survival rate achieved by the combination of IP paclitaxel, IP cisplatin, and IV paclitaxel in women with optimally debulked, stage III ovarian cancer. PATIENTS AND METHODS: Treatment consisted of paclitaxel 135 mg/m(2) IV over 24 hours on days 1 to 2, cisplatin 100 mg/m(2) IP on day 2, and paclitaxel 60 mg/m(2) IP on day 8 administered every 21 days for six cycles. RESULTS: In 68 assessable women with optimal stage III ovarian cancer, the 2-year survival rate was 91%, and the median survival time was 51 months. The 2-year disease-free survival rate was 66%, and median disease-free survival time was 33 months. Ninety-six percent of all patients experienced at least one grade 3 to 4 adverse event during therapy, with the most common events being neutropenia (79%), nausea (50%), vomiting (34%), and fatigue/malaise/lethargy (24%). Seventy-one percent of patients completed all six cycles of IV/IP therapy as planned. CONCLUSION: Combined IV and IP chemotherapy with cisplatin and paclitaxel is associated with a very promising 2-year survival rate in women with optimally debulked ovarian cancer. The ultimate impact of this approach on overall survival requires further evaluation in a randomized trial setting. 相似文献
13.
目的:观察顺铂腹腔联合紫杉醇静脉化疗治疗中晚期卵巢癌术后患者的临床疗效和安全性.方法:回顾性分析我院2006-01-2009-12行细胞减灭术Ⅱ~Ⅳ期卵巢癌76例患者,顺铂腹腔联合紫杉醇静脉化疗36例为治疗组,并以同期行顺铂联合紫杉醇静脉化疗患者40例作为对照.比较两组患者无进展生存期(PFS)、生存率和不良反应.结果:治疗组PFS 27个月,对照组PFS 23个月,P<0.05.治疗组1、2和3年生存率分别为97.22%(35/36)、94.44%(34/36)和88.88%(32/36),对照组1、2和3年生存率分别为95.00%(38/40)、90.00%(36/40)和77.50%(31/40).治化疗组呕吐及肾功能损伤低于对照组,而腹痛高于对照组.结论:顺铂腹腔联合紫杉醇静脉化疗治疗中晚期卵巢癌术后患者可延长患者PFS及生存率,毒副反应轻,值得临床应用. 相似文献
14.
紫杉醇腹腔灌注化疗治疗晚期卵巢癌临床研究 总被引:1,自引:0,他引:1
目的:探讨紫杉醇(PTX)腹腔灌注化疗联合顺铂(PDD)全身化疗治疗晚期卵巢癌患者的疗效和安全性。方法:2006年1月至2010年1月,给予33例TNMⅢ-Ⅳ期卵巢癌患者(Ⅲ期20例,Ⅳ期13例)PTX60mg/m2ip d1,5,10,PDD 40mg/m2iv d1-2,每21天为1周期,共2-4个周期,每2周期评定疗效。结果:总有效率(RR,CR+PR)为78.79%,其中CR 60.61%、PR 18.18%。中位疾病进展时间(TTP)为22.3个月。2年生存率为81.82%。常见不良反应为骨髓抑制、腹痛、腹泻、胃肠道反应、脱发、口腔黏膜炎和肌肉关节痛等。结论:PTX 60mg/m2腹腔灌注d1,5,10联合PDD 40mg/m2静脉滴注d1,2方案治疗晚期卵巢癌疗效肯定,且不良反应可以耐受。 相似文献
15.
Z Kojs B Glinski M Reinfuss J Pudelek K Urbanski T Kowalska J Kulpa 《Cancer radiothérapie》2001,5(1):5-11
PURPOSE: In a prospective randomized trial, our aim was to evaluate and compare the tolerance and efficacy of postoperative radiotherapy and chemotherapy in the treatment of early ovarian cancer. MATERIAL AND METHODS: Between 1990 and 1996, 150 patients with ovarian cancer stage IA, IB grades G2-3, and all patients classified IC and IIA, who did not have evidence of residual disease after surgery, were randomized to two treatment branches: radiotherapy or chemotherapy (CH). In the radiotherapy branch (76 patients), a whole abdomen irradiation of 30 Gy in 24 fractions over 5 weeks, with a pelvic boost to 50 Gy, was delivered. In the chemotherapy branch (74 patients), there were six series of polychemotherapy separated with 3-weeks interval. In each series patients received association of cisplatin (50 mg/m2, d1), adriamycin (50 mg/m2, d1) and cyclophosphamide (500 mg/m2, d1). RESULTS: The tolerance of the treatment was good and comparable in both groups. In the radiotherapy branch, three late grade G3 intestinal complications were observed (three bowel obstructions, which required surgery in two cases). The actuarial survival rate without evidence of disease was 81% at 5 years for both groups. In our series we found that histological grade had the strongest influence on survival prognosis; it was the only significant factor in a multivariate analysis. Patients with grade G3 tumors had the worst survival. CONCLUSION: These data suggest that efficacy of postoperative radiotherapy and chemotherapy administered to our patients with early ovarian cancer gave approximately identical results. 相似文献
16.
A de Gramont B Demuynck C Louvet G Gonzalez-Canali C Varette A Pigné L Marpeau P Herbulot B Lagadec J Cady 《American journal of clinical oncology》1992,15(1):7-11
We studied survival in 36 patients with Stage III/IV ovarian cancer who received intraperitoneal high-dose cisplatin (200 mg/m2) alone or in combination with cytarabine (2 g), after intravenous (i.v.) cisplatin-based chemotherapy followed by second-look laparotomy. Complete responders were scheduled for three courses of IP chemotherapy, and others for six. Eight patients (22%) did not complete treatment (6 catheter failures and 2 renal failures). Peritoneal cytology remained positive in 6 patients (17%). Median overall and progression-free survival after second-look laparotomy were 44 and 37 months, respectively, for 13 complete responders to i.v. chemotherapy; 24 months and 11 months for patients with residual tumors less than 2 cm (17 cases); 15 and 12 months with tumors greater than 2 cm (6 cases). There was a significant difference in overall (p = 0.05) and progression-free (p = 0.001) survival between complete responders to i.v. chemotherapy and patients whose tumor was less than 2 cm. We find no evidence that high-dose cisplatin-based intraperitoneal chemotherapy given after second-look laparotomy will enhance survival in advanced ovarian cancer with zero or minimal residual disease. 相似文献
17.
目的:探究术中动脉灌注化疗(intraoperation artery infusion chemotherapy,IAIC)联合腹腔灌注化疗对胃癌患者预后的影响。方法:筛选2006年3月-2007年9月就诊于我科的91例年龄≤75岁的胃癌患者随机分为实验组(47例)和对照组(44例)。实验组术中经瘤体的主要供血动脉及腹腔共给予5-氟尿嘧啶1000mg及丝裂霉素10mg,对照组给予等体积生理盐水后单纯行常规手术切除,术后两组患者均给予FAP方案(5-氟尿嘧啶600mg/m2d1、丝裂霉素30mg/m2 d1、顺铂20mg/m2 d1-5)化疗,总疗程4-6次。结果:实验组1年、2年、3年生存率分别为89.36%、76.09%、58.70%。3年局部复发率、腹腔转移率、肝脏转移率分别为26.09%、15.22%、21.74%。对照组1年、2年、3年生存率分别为90.91%、60.47%、32.56%。3年局部复发率、腹腔转移率、肝脏转移率分别为46.51%、25.58%、18.60%。中位生存时间实验组为36个月,而对照组为27个月。两组间3年腹腔转移率差异较大,但无统计学意义(P>0.05)。3年生存率及局部复发率的差异有统计学意义(P<0.05)。结论:术中动脉灌注联合腹腔灌注5-氟尿嘧啶及丝裂霉素,可有效提高患者的远期生存率,同时降低局部复发率。并对腹腔转移率的降低可能有意义。 相似文献
18.
M Markman B N Bundy D S Alberts J M Fowler D L Clark-Pearson L F Carson S Wadler J Sickel 《Journal of clinical oncology》2001,19(4):1001-1007
PURPOSE: To compare the progression-free and overall survival in small-volume residual ovarian cancer after treatment with intravenous (IV) cisplatin and paclitaxel or an experimental regimen of IV carboplatin followed by IV paclitaxel and intraperitoneal cisplatin. PATIENTS AND METHODS: Patients were randomized to receive either IV paclitaxel 135 mg/m(2) over 24 hours followed by IV cisplatin 75 mg/m(2) every 3 weeks for six courses or IV carboplatin (area under curve 9) every 28 days for two courses, then IV paclitaxel 135 mg/m(2) over 24 hours followed by intraperitoneal (IP) cisplatin 100 mg/m(2) every 3 weeks for six courses. RESULTS: Of the 523 patients who entered this trial, 462 were determined to be assessable, with prognostic factors well balanced between the treatments. Neutropenia, thrombocytopenia, and gastrointestinal and metabolic toxicities were greater in the experimental arm. As a result, 18% of the patients received < or = two courses of IP therapy. Progression-free survival was superior for patients randomized to the experimental treatment arm (median, 28 v 22 months; relative risk, 0.78; log-rank P =.01, one-tail). There was a borderline improvement in overall survival associated with this regimen (median, 63 v 52 months; relative risk, 0.81; P =.05, one-tail). CONCLUSION: An experimental regimen including moderately high-dose IV carboplatin followed by IP paclitaxel and IV cisplatin yielded a significant improvement in progression-free survival when compared with a standard regimen of IV cisplatin and paclitaxel. Because the improvement in overall survival was of borderline statistical significance and toxicity was greater, the experimental arm is not recommended for routine use. However, the results provide direction for further clinical investigation in small-volume ovarian cancer. 相似文献
19.
目的 观察全身化疗联合腹腔化疗对晚期卵巢癌的疗效及毒副反应.方法 24例卵巢癌,用紫杉醇135 mg/m2,卡铂400 mg/m2静滴,每4周重复1次,共化疗2个周期,顺铂60 mg,地塞米松10 mg腹腔化疗,每2周1次,进行2~3个周期,中位疾病进展时间(MTTP)9个月(5~12个月),无复发生存期5个月,观察每次化疗毒副反应及疗效.结果 24例中CR 12例、PR 7例,RR 79.2%,毒副反应为剂量限制性骨髓抑制、消化道反应.结论 全身化疗联合腹腔化疗对晚期卵巢癌有较好疗效. 相似文献